This is why we strongly recommend: Using a cycling protocol (periods of use followed by planned breaks) rather than continuous, indefinite use
96 participants were randomly assigned to groups of 6 multiple-ascending doses of once-weekly subcutaneous cagrilintide (final doses of 0.16, 0.30, 0.60, 1.2, 2.4, and 4.5 mg) in combination with once-weekly subcutaneous semaglutide 2.4 mg or semaglutide 2.4 mg with placebo for 20 weeks
Cardiovascular and muscle cells The detection of PET MNPs as one of the predominant polymers in the circulatory system, including blood and cardiac-associated tissues, even within deep-seated structures, raises legitimate concerns about potential direct impacts on cardiovascular health
Wegovy has been associated with serious gastrointestinal complications, including stomach paralysis and intestinal obstruction, leading to numerous reports of these issues to the FDA
How often can I get IV therapy
Joanna K